Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) insider Howard Lazarus sold 13,300 shares of the stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $27.90, for a total transaction of $371,070.00. Following the transaction, the insider owned 13,300 shares of the company’s stock, valued at $371,070. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Avalyn Pharma Stock Performance
Avalyn Pharma stock traded up $1.01 during mid-day trading on Thursday, reaching $28.70. The company’s stock had a trading volume of 437,291 shares, compared to its average volume of 344,822. The company has a debt-to-equity ratio of 0.04, a current ratio of 25.76 and a quick ratio of 25.76. Avalyn Pharma Inc. has a 12 month low of $22.24 and a 12 month high of $40.17. The firm’s 50 day simple moving average is $28.15. The stock has a market cap of $1.28 billion and a P/E ratio of -1.26.
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.03). As a group, sell-side analysts expect that Avalyn Pharma Inc. will post -3.87 EPS for the current year.
Institutional Trading of Avalyn Pharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in AVLN. Montanova Capital LLC bought a new position in shares of Avalyn Pharma in the 2nd quarter valued at about $82,402,000. Soleus Capital Management L.P. increased its stake in shares of Avalyn Pharma by 143.2% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,019,000 shares of the company’s stock worth $29,031,000 after purchasing an additional 600,000 shares during the last quarter. Braidwell LP bought a new stake in shares of Avalyn Pharma in the 2nd quarter valued at about $26,382,000. State Street Corp raised its holdings in shares of Avalyn Pharma by 73.7% in the 3rd quarter. State Street Corp now owns 554,004 shares of the company’s stock valued at $15,784,000 after purchasing an additional 235,009 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Avalyn Pharma in the 2nd quarter valued at about $1,321,000.
Analysts Set New Price Targets
A number of research firms recently issued reports on AVLN. Morgan Stanley lowered their target price on Avalyn Pharma from $57.00 to $53.00 and set an “overweight” rating on the stock in a research report on Monday. Raymond James Financial initiated coverage on Avalyn Pharma in a research report on Friday, October 2nd. They set an “outperform” rating and a $60.00 price target for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Finally, Wall Street Zen raised Avalyn Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $59.20.
Read Our Latest Report on Avalyn Pharma
About Avalyn Pharma
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.
See Also
- Five stocks we like better than Avalyn Pharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
